New COVID WAVE “PLANNED”? BioNTech is Expecting Pandemic-Level Vaccine Sales in Autumn…
The Tour de France cycling race terrorized by Covid
by Carlo Domenico Cristofori
The Tour de France has strengthened protection measures to “limit health risks” in the face of the resurgence of Covid-19 that has affected several riders in recent days.
Wearing a mask is now mandatory for all people (organizers, guests, journalists, etc.) “in contact with the riders and members of the cycling teams” before and after the stages, the organizers of Amaury Sport Organization (ASO) indicated.
Several riders, including the British Tom Pidcock and the Spaniard Juan Aysuo, teammate of the yellow jersey Tadej Pogacar, withdrew after the positive Covid test. Pogacar had declared before the start of the match that he had been affected by the virus in mid-June. Geraint Thomas, winner of the Tour in 2018, continues the race for the moment despite having “mild symptoms”.
Many cyclists have already started wearing masks for days, such as Remco Evenepoel, third overall, who explained that he did so because the journalists in front of him were not wearing them.
The fact that one of the most important French events is frightened by a new Covid wave just on the eve of the next Paris Olympics represents a signal for two reasons.
Scandal over Stockholm University for a “Banned” Study on Turbo-Cancer linked to Covid Vaccines
The SARS-Cov-2 virus was built in the laboratory as confirmed by multiple scientific research and by the US Senate but this circumstance is continually denied by the European Commission which was the first to finance the dangerous experiments on SARS at the Wuhan Institute of Virology, where they were created Gain of Function enhanced coronavirus strains.
But in European countries it is forbidden to talk about it! Just as it is forbidden to reiterate too emphatically the risk of damage to the immune system and turbo-cancer deriving from mRNA gene sera.
The Covid disease is often asymptomatic and easily treatable with aspirin, anti-inflammatories and, only in the most serious cases, antibiotics but a herbal medicine obtained from South African genranium is also effective against it.It is therefore clear that the new media terrorism seems aimed at justifying a new autumn vaccination campaign after the failure of the 2023 ones.
And just as Ursula von Der Leyen is going to be reconfirmed as president of the European Commission (despite being under investigation by the EPPO European Prosecutor’s Office for the secret purchase of Pfizer-Biontech’s Comirnaty vaccines) the German company like her is already making exceptional predictions…
Why is BioNTech Expecting Pandemic-Level Vaccine Sales in the Autumn?
Originally published by Robert Kogon
The German mRNA company BioNTech, owner and legal manufacturer of what is more commonly known as the “Pfizer” COVID-19 vaccine, has fallen on hard times. Well, not so hard, given that BioNTech cleared nearly €30 billion in profits on sales of the product during 2021 and 2022 and still has a reported €18 billion in cash or cash equivalents on hand.
But, in any case, with no other product authorised for use and the market for COVID-19 vaccines, needless to say, having crashed, BioNTech has gone back to losing money. This was all it ever did in fact from the time of its founding in 2008 until 2021, and, as reported in a recent article in the German daily Der Tagesspiegel, the firm booked €300 million in losses in the first quarter of 2024 on €187.6 million in sales.
“Pfizer-Biontech Vaccine Batches in the EU Were Placebos” Say Scientists of German Universities
But apparently the firm is confident that good times – for it, at any rate – are just around the corner, since, according to its projections, it will achieve total sales roughly 15 times greater than that for 2024 as a whole: namely, between €2.5 and €3.1 billion. Thus, BioNTech Chief Financial Officer Jens Holstein notes: “We expect to achieve around 90% of our total annual sales in the final months of 2024, primarily in the fourth quarter of 2024.”
Even Der Tagesspiegel finds these projections surprising – or “ambitious”, as the paper puts it. Thus, it notes:
In 2023, [BioNTech’s] fourth quarter sales did not even account for 40% of total sales, and in 2022 it was even less at barely 25%. Even the entire second half of 2023 accounted altogether for just 62.2% of total sales. In each of the last two years, BioNTech achieved a third of total sales already in the first quarter.
Let’s take BioNTech’s projected 2024 total sales of from €2.5 to €3.1 billion and split the difference, assuming that total sales will come in at €2.8 billion for the year. 90% of €2.8 billion is €2.52 billion.
This is 13 times greater than the first quarter figure. But given what is now widely accepted as the flu-like seasonality of Covid infections, the first quarter should be just as much a “good” quarter for Covid products as the fourth quarter – and this is borne out in the aforementioned figures from Der Tagesspiegel.
Moreover, the €2.5 billion in projected fourth quarter sales is not far off the astronomical quarterly sums that BioNTech was pulling in during the high Covid period. In the second quarter of 2022, for instance, BioNTech had €3.2 billion in sales. In the fourth quarter of 2022, it had €4.3 billion.
Why is the firm expecting to make so much money in the autumn? Does BioNTech know something that we don’t?
Originally published by Robert Kogon and republished by The Daily Sceptic
Robert Kogon is the pen name of a widely-published journalist covering European affairs. Subscribe to his Substack.
All the links to Gospa News articles have been added in the aftermath
https://www.gospanews.net/en/2023/03/25/toxic-nanoforms-inside-pfizer-biontech-covid-vaccine-exclusive-study-by-italian-biochemist-on-us-journal-of-virology-highlighted-alleged-crime/
